Home Regular Therapy in PracticeRegular ICS in asthma guidelines and recommendations

Regular ICS in asthma guidelines and recommendations

Guidelines and recommendations include regular ICS for asthma management

• 5-minute read

Goals of asthma treatment

goals of optimal asthma treatmentgoals of optimal asthma treatment

Optimal asthma management involves the management of pulmonary and extrapulmonary factors1

optimal asthma management involves the management of pulmonary and extrapulmonary factors
Next Section

Most international guidelines recommend a step-wise approach to asthma management, if asthma control cannot be achieved1-11

most international guidelines recommend a step-wise approach to asthma managementmost international guidelines recommend a step-wise approach to asthma management

Step-up/down as needed to achieve symptom control1-11

differences between individual guidelines can lead to HCP confusion around best practice
Next Section

Recommendations for regular ICS

GINA 2022 recommendations propose two treatment tracks for asthma managementGINA 2022 recommendations propose two treatment tracks for asthma management
many national guidelines advocate regular ICS dosing regimens for mild/moderate asthma
many national guidelines advocate regular ICS dosing regimens for mild/moderate asthmamany national guidelines advocate regular ICS dosing regimens for mild/moderate asthma

*ICS/formoterol is licensed for maintenance and reliever therapy (MART) or regular maintenance use only in the UK. Please refer to your local SmPC prior to prescribing.

Next Section

Summary of asthma guidelines

National and global guidelines advocate for the use of regular ICS to treat the underlying inflammation in patients with asthma1-11
For more information on recommendations for the regular use of ICS-containing therapies in your location, please contact your local representative here

Abbreviations

GINA, Global Initiative for Asthma; HCP, healthcare professional; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; SABA, short-acting β2-agonist; T2, Type-2; SmPC, summary of product characteristics.

References

1. Global Initiative for Asthma 2022 Report. Global Strategy for asthma management and prevention. Available from: https://ginasthma.org/gina-reports/. Accessed 16 March 2023;

2. BTS/SIGN 2019. Available from: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed 16 March 2023;

3. NICE guideline NG-80. Available from: https://www.nice.org.uk/guidance/ng80. Accessed 16 March 2023;

4. Nakamura Y, et al. Allergol Int 2020;69:519e548;

5. Plaza V, et al. Arch Bronconeumol 2022;58(2):T150–T158;

6. Yang CL, et al. Critical Care, and Sleep Medicine 2021;5(4):205–45;

7. Agency for Care Effectiveness 2020. Available from: https://www.ace-hta.gov.sg/docs/default-source/acgs/asthma-management-(nov-2020).pdf. Accessed 16 March 2023;

8. National Asthma Council. Available from: https://www.nationalasthma.org.au/health-professionals/australian-asthma-handbook. Accessed 16 March 2023;

9. Pizzichini MMM, et al. J Bras Pneumol 2020;46(1):e20190307;

10. KATRD. Asthma treatment guidelines 2022, 5th revision. Available from: https://nl.go.kr/seoji/contents/S80100000000.do?schM=intgr_detail_view_isbn&isbn=9791191073010. Accessed 16 March 2023;

11. Cloutier MM, et al. JAMA 2020;324:2301–17.

NX-GBL-ASU-WCNT-220008 | March 2023

Related media

Continue your learning with these related resources

Infographicnew Badge

INFOGRAPHIC

Appropriate use of SABA

10-minute read

Webinarnew Badge

VIDEO

APPaRENT: physician perspectives

20-minute watch

Case Studynew Badge

INTERACTIVE

Patient case: Deirdre

10-minute activity